Gentronix Joins Scantox Brand Amid Expansion Efforts

Scantox Group announced the integration of Gentronix under its brand, rebranding it as Scantox Manchester. Acquired in 2024, Gentronix's inclusion signifies Scantox's focus on expanding its genetic toxicology and genomic safety services. The integration brings Gentronix's expertise and client relations into Scantox, offering enhanced capabilities and resources.

Since the acquisition, Scantox expanded its services including the Big Blue® transgenic rodent assay and the DuplexSeq™ genomic safety operations. These expansions position Scantox as a leading provider of mutagenic risk assessment tools. Key leadership roles have also been adjusted, with Matt Tate and Laura Hinton assuming significant positions.

Scantox's advancements indicate an industry shift in mutagenic risk evaluation, aiming to offer comprehensive genomic safety data from initial screenings to regulatory submissions.